EGFR and neoplasm: Compared with clinical examinations such as direct sequencing of PCR-amplified genomic DNA, high-resolution melting analysis, fragment analysis, and the amplification refractory mutation system,[30] which are generally expensive and sometimes do not have a high rate of tumor cell detection, the scoring model described in this can not only discriminate EGFR-mutated subtypes (exon 19 deletion) but also are noninvasive and less expensive, especially for advanced NSCLC patients who cannot receive biopsy.[31]